Pee test could spot rare cancer earlier
NCT ID NCT06805630
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study is testing whether a urine test that looks for DNA markers can help diagnose and monitor upper tract urothelial cancer (UTUC), a rare cancer of the kidney and ureter. Researchers will collect urine samples from 50 patients before surgery and during follow-up visits. The test results will be compared to standard methods like urine cell analysis and tissue biopsy to see if the new approach is accurate and useful.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Urine methylation biomarker test (Bladder CARE™)
- What this could lead to
- If successful, this urine test could offer a simpler, less invasive way to detect and monitor upper tract urothelial cancer, potentially catching recurrences earlier.
- What could go wrong
- This is a small, early-stage study with only 50 participants. The test may not prove accurate enough to replace current methods, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.